FDA Grants Breakthrough Therapy Designation to VERTANICAL's VER-01, a First-in-Class Non-Opioid Investigational Treatment for Chronic Low Back Pain
PRNewsWire
·
2026-05-18
·
via The Tech Buzz - Press Releases
GRÄFELFING, Germany, May 18, 2026 /PRNewswire/ -- VERTANICAL today announced that the U.S. Food and Drug Admi…
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。
